论文部分内容阅读
目的研究乙型肝炎表面抗原(HBsAg)携带者孕妇及其新生儿应用乙肝免疫球蛋白(HBIG)对阻断乙肝母婴传播的效果。方法A组64例,于孕28、32、36周分别注射HBIG200U,B组64例仅常规产前检查及监护。新生儿分为Ⅰ、Ⅱ、Ⅲ组,Ⅰ、Ⅱ组新生儿注射乙肝疫苗(HBVac)10μg和HBIG100U,Ⅲ组新生儿只注射乙肝疫苗10μg。结果A组较B组新生儿外周血HBsAg阳性率显著降低(P<0.05)。Ⅰ、Ⅲ组婴儿6个月龄HBsAg阳性率差异有统计学意义(P<0.05)。结论对HBsAg携带者孕晚期应用HBIG可以显著降低新生儿外周血HBsAg阳性率;对HBsAg携带者孕晚期应用HBIG,新生儿出生时应用HBIG和HBVac联合免疫,可以显著提高婴儿6个月龄HBsAb的阳性率。
Objective To study the effect of hepatitis B immunoglobulin (HBIG) on the prevention of mother-to-child transmission of hepatitis B in pregnant women and their newborns with carriers of hepatitis B surface antigen (HBsAg). Methods A group of 64 cases, 28,32,36 weeks of pregnancy were injected with HBIG200U, B group 64 cases only conventional antenatal examination and custody. Newborns were divided into Ⅰ, Ⅱ and Ⅲ groups. Newborns in groups Ⅰ and Ⅱ were given 10 μg hepatitis B vaccine (HBVac) and 100 μg HBIG. Neonates in group Ⅲ received only 10 μg hepatitis B vaccine. Results The positive rate of HBsAg in group A was significantly lower than that in group B (P <0.05). The positive rates of HBsAg at 6 months in infants of group Ⅰ and Ⅲ were significantly different (P <0.05). Conclusion The application of HBIG in HBsAg recipients in the third trimester can significantly reduce the positive rate of HBsAg in the peripheral blood of newborn infants. When HBIG is used in the third trimester of pregnancy, combined HBIG and HBVac co-immunization can significantly increase the 6-month-old HBsAb Positive rate.